Alberto Coustasse, DrPH, MD, MBA, MPH

With Oregon, Colorado, and New Mexico legalizing psilocybin-assisted therapy, opportunities for treatment are expanding.

PBM reforms and regulatory changes have reshaped the industry landscape.

AI is significantly enhancing the efficiency of identifying and enrolling patients.

Innovations are expanding opportunities for care.

Clinical trials are using AI to handle large and complex volumes of data to develop oncology, cardiovascular, and neurologic compounds and to integrate molecular and imaging data.

Successful integration demands overcoming various hurdles.

High nonadherence in the US leads to avoidable mortality.

Safe handling of hazardous drugs plays a vital role in patient care.

AI systems can detect minute anomalies often missed by the human eye, reducing false negatives.